TAK · Company research
3 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Zasocitinib regulatory submissions in plaque psoriasis (US NDA and other authorities), expected during 2026 (no exact date yet). A company milestone for Takeda Pharmaceutical Company (Zasocitinib (TAK-279) for Moderate-to-severe plaque psoriasis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Takeda Capital Markets Day in Tokyo, expected on Dec 11, 2026. A company milestone for Takeda Pharmaceutical Company (Pipeline (oveporexton, rusfertide, zasocitinib, mezagitamab, fazirsiran, elritercept) for Corporate/pipeline strategy): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Zasocitinib psoriasis US filing in FY2026; launch targeted H1 2027, expected in the first half of 2027 (no exact date yet). A company milestone for Takeda Pharmaceutical Company (Zasocitinib (TAK-279, oral TYK2 inhibitor) for Moderate-to-severe plaque psoriasis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Takeda Pharmaceutical Company’s Rusfertide for Polycythemia vera was due in Aug 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Takeda Pharmaceutical Company’s Rusfertide (hepcidin mimetic; with Protagonist Therapeutics) for Polycythemia vera was due in Q3 2026 (Jul–Sep). The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Japanese regulators approved Takeda Pharmaceutical Company’s Orzeyful (oveporexton, TAK-861) for Narcolepsy type 1 in Q3 2026 (Jul–Sep). The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Takeda Pharmaceutical Company presented data on Zasocitinib (TAK-279) for Moderate-to-severe plaque psoriasis at a medical meeting on Jul 16, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Takeda Pharmaceutical Company presented data on Oveporexton (TAK-861) for Narcolepsy type 1 at a medical meeting on Jun 15, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Takeda Pharmaceutical Company reported results from its Phase 3 study of Zasocitinib (TAK-279) for Moderate-to-severe plaque psoriasis on Jun 11, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Takeda Pharmaceutical Company presented data on Zasocitinib (TAK-279) for Moderate-to-severe plaque psoriasis at a medical meeting on Mar 28, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Takeda Pharmaceutical Company’s Rusfertide for Polycythemia vera on Mar 2, 2026. That clears it for sale in the US.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to TAK.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.